Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Prostate Cancer | Research

Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer

Authors: Yelisudan Mulati, Cong Lai, Jiawen Luo, Jintao Hu, Xiaoting Xu, Degeng Kong, Yunfei Xiao, Cheng Liu, Kewei Xu

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Purpose

Prostate cancer (PCa) is one of the major tumor diseases that threaten men’s health globally, and biochemical recurrence significantly impacts its prognosis. Disulfidptosis, a recently discovered cell death mechanism triggered by intracellular disulfide accumulation leading to membrane rupture, is a new area of research in the context of PCa. Currently, its impact on PCa remains largely unexplored. This study aims to investigate the correlation between long non-coding RNAs (lncRNAs) associated with disulfidptosis and the prognosis of PCa, seeking potential connections between the two.

Methods

Transcriptomic data for a PCa cohort were obtained from the Cancer Genome Atlas database. Disulfidptosis-related lncRNAs (DDRLs) were identified through differential expression and Pearson correlation analysis. DDRLs associated with biochemical recurrence-free survival (BRFS) were precisely identified using univariate Cox and LASSO regression, resulting in the development of a risk score model. Clinical factors linked to BRFS were determined through both univariate and multivariate Cox analyses. A prognostic nomogram combined the risk score with key clinical variables. Model performance was assessed using Receiver Operating Characteristic (ROC) curves, Decision Curve Analysis (DCA), and calibration curves. The functional impact of a critical DDRL was substantiated through assays involving CCK8, invasion, migration, and cell cloning. Additionally, immunohistochemical (IHC) staining for the disulfidptosis-related protein SLC7A11 was conducted.

Results

The prognostic signature included AC026401.3, SNHG4, SNHG25, and U73166.1 as key components. The derived risk score from these signatures stood as one of the independent prognostic factor for PCa patients, correlating with poorer BRFS in the high-risk group. By combining the risk score with clinical variables, a practical nomogram was created, accurately predicting BRFS of PCa patients. Notably, silencing AC026401.3 significantly hindered PCa cell proliferation, invasion, migration, and colony formation. IHC staining revealed elevated expression of the dithiosulfatide-related protein SLC7A11 in tumor tissue.

Conclusions

A novel prognostic signature for PCa DDRLs, possessing commendable predictive power, has been constructed, simultaneously providing potential therapeutic targets associated with disulfidptosis, among which AC026401.3 has been validated in vitro and demonstrated inhibition of PCa tumorigenesis after its silencing.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
go back to reference Ishikawa H, et al. The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of Prostate cancer after prostatectomy. J Radiat Res. 2020;61(6):908–19.CrossRefPubMedPubMedCentral Ishikawa H, et al. The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of Prostate cancer after prostatectomy. J Radiat Res. 2020;61(6):908–19.CrossRefPubMedPubMedCentral
4.
go back to reference Liu X, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol. 2020;22(4):476–86.CrossRefPubMedPubMedCentral Liu X, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol. 2020;22(4):476–86.CrossRefPubMedPubMedCentral
5.
go back to reference Joly JH, et al. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020;295(5):1350–65.CrossRef Joly JH, et al. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020;295(5):1350–65.CrossRef
7.
go back to reference Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016;1859(1):169–76.CrossRef Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016;1859(1):169–76.CrossRef
8.
go back to reference Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in Breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Research: BCR. 2015;17:40.CrossRefPubMedPubMedCentral Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in Breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Research: BCR. 2015;17:40.CrossRefPubMedPubMedCentral
9.
10.
go back to reference Jiang C, et al. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma. Pharmacol Res. 2021;169:105644.CrossRefPubMed Jiang C, et al. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma. Pharmacol Res. 2021;169:105644.CrossRefPubMed
11.
go back to reference Zuo S, et al. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell Lung cancer. J Translational Med. 2019;17(1):152.CrossRef Zuo S, et al. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell Lung cancer. J Translational Med. 2019;17(1):152.CrossRef
12.
go back to reference Feng Z-H et al. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer Journal of Translational Medicine, 2022. 20(1): p. 492. Feng Z-H et al. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer Journal of Translational Medicine, 2022. 20(1): p. 492.
13.
go back to reference Wang Y, et al. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma. Exp Cell Res. 2022;420(1):113335.CrossRefPubMed Wang Y, et al. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma. Exp Cell Res. 2022;420(1):113335.CrossRefPubMed
14.
go back to reference Liu L, et al. Disulfidptosis-associated LncRNAs index predicts prognosis and chemotherapy Drugs sensitivity in Cervical cancer. Sci Rep. 2023;13(1):12470.CrossRefPubMedPubMedCentral Liu L, et al. Disulfidptosis-associated LncRNAs index predicts prognosis and chemotherapy Drugs sensitivity in Cervical cancer. Sci Rep. 2023;13(1):12470.CrossRefPubMedPubMedCentral
15.
go back to reference Jiang C, et al. Prognosis prediction of disulfidptosis-related genes in Bladder Cancer and a comprehensive analysis of Immunotherapy. Crit Rev Eukaryot Gene Expr. 2023;33(6):73–86.CrossRefPubMed Jiang C, et al. Prognosis prediction of disulfidptosis-related genes in Bladder Cancer and a comprehensive analysis of Immunotherapy. Crit Rev Eukaryot Gene Expr. 2023;33(6):73–86.CrossRefPubMed
16.
17.
18.
go back to reference Chen C, et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic Metastasis in Bladder cancer. J Clin Invest. 2020;130(1):404–21.CrossRefPubMed Chen C, et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic Metastasis in Bladder cancer. J Clin Invest. 2020;130(1):404–21.CrossRefPubMed
19.
go back to reference May EJ, et al. Prostate cancer post-treatment follow-up and recurrence evaluation. Abdom Radiol (New York). 2016;41(5):862–76.CrossRef May EJ, et al. Prostate cancer post-treatment follow-up and recurrence evaluation. Abdom Radiol (New York). 2016;41(5):862–76.CrossRef
20.
go back to reference Zumsteg ZS, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for Prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67(6):1009–16.CrossRef Zumsteg ZS, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for Prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67(6):1009–16.CrossRef
21.
go back to reference Hovelson DH, Tomlins SA. The role of Next-Generation sequencing in castration-resistant Prostate Cancer Treatment. Cancer J (Sudbury Mass). 2016;22(5):357–61.CrossRef Hovelson DH, Tomlins SA. The role of Next-Generation sequencing in castration-resistant Prostate Cancer Treatment. Cancer J (Sudbury Mass). 2016;22(5):357–61.CrossRef
22.
go back to reference Sato H, et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999;274(17):11455–8.CrossRef Sato H, et al. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999;274(17):11455–8.CrossRef
23.
go back to reference Koppula P, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (London England). 2018;38(1):12. Koppula P, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (London England). 2018;38(1):12.
25.
go back to reference Zhang D, et al. An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma. Front Oncol. 2023;13:1207068.CrossRefPubMedPubMedCentral Zhang D, et al. An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma. Front Oncol. 2023;13:1207068.CrossRefPubMedPubMedCentral
26.
go back to reference Pettersson A, et al. Age at diagnosis and Prostate cancer treatment and prognosis: a population-based cohort study. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018;29(2):377–85.CrossRef Pettersson A, et al. Age at diagnosis and Prostate cancer treatment and prognosis: a population-based cohort study. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018;29(2):377–85.CrossRef
27.
go back to reference Braunhut BL, Punnen S, Kryvenko ON. Updates on grading and staging of Prostate Cancer. Surg Pathol Clin. 2018;11(4):759–74.CrossRef Braunhut BL, Punnen S, Kryvenko ON. Updates on grading and staging of Prostate Cancer. Surg Pathol Clin. 2018;11(4):759–74.CrossRef
29.
go back to reference Deng Y, et al. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma. Front Immunol. 2022;13:1046790.CrossRefPubMedPubMedCentral Deng Y, et al. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma. Front Immunol. 2022;13:1046790.CrossRefPubMedPubMedCentral
30.
go back to reference Bai Z et al. Identification and validation of cuproptosis-related LncRNA signatures in the prognosis and immunotherapy of Clear Cell Renal Cell Carcinoma using machine learning. Biomolecules, 2022. 12(12). Bai Z et al. Identification and validation of cuproptosis-related LncRNA signatures in the prognosis and immunotherapy of Clear Cell Renal Cell Carcinoma using machine learning. Biomolecules, 2022. 12(12).
31.
go back to reference Huang E, et al. The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the Tumor microenvironment of patients with hepatocellular carcinoma. Annals of Translational Medicine. 2022;10(14):766.CrossRefPubMedPubMedCentral Huang E, et al. The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the Tumor microenvironment of patients with hepatocellular carcinoma. Annals of Translational Medicine. 2022;10(14):766.CrossRefPubMedPubMedCentral
32.
Metadata
Title
Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer
Authors
Yelisudan Mulati
Cong Lai
Jiawen Luo
Jintao Hu
Xiaoting Xu
Degeng Kong
Yunfei Xiao
Cheng Liu
Kewei Xu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11778-2

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine